Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | -.--% | +35.54% |
May. 24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
May. 24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.54% | 1.31B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-5.78% | 13.3B | |
-11.38% | 11.65B | |
-49.84% | 10.12B | |
+5.24% | 9.06B |
- Stock Market
- Equities
- 2696 Stock
- News Shanghai Henlius Biotech, Inc.
- Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint